Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in heterozygous familial hypercholesterolemia inadequately controlled on statins
2012-001222-95Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Alirocumab add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Percent change in LDL-C at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2012-001222-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001222-95.